Catalyst Biosciences Stock News

The stock option was granted as an inducement material to Mr. Musil’s entering into employment with Catalyst in accordance with Nasdaq Listing Rule 5635(c)(4). The stock option was granted outside

SOUTH SAN FRANCISCO, Calif., June 29, 2020 -- Catalyst Biosciences, Inc. (NASDAQ: CBIO), today announced two presentations at the upcoming International Society on Thrombosis.

Análisis de Acciones por Salva Fuster cubriendo: AXA SA, Volkswagen AG VZO O.N.. Lea los Análisis de Acciones de Salva Fuster en Investing.com.

The gross proceeds to Catalyst from this offering were approximately $30.0 million, before deducting underwriting discounts and commissions and other estimated offering expenses payable by Catalyst.

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on InflaRx (IFRX –

Mr. Democko brings over 20 years of regulatory affairs experience in the development of both biologics and small molecules ranging from pre-IND through commercial stage companies across several therap

The oral presentation, entitled: “Combination of a Novel Chimeric AAV Capsid and Potency Enhanced FIX Variant for Hemophilia B Gene Therapy,” given by Dr. Grant Blouse, senior vice president of tr

The biggest life sciences deal this week involves a company that doesn’t discover or develop drugs, or even sell them. Yet its mark is found on

Additionally, Catalyst has granted the underwriters a 30-day option to purchase up to an additional 692,307 shares of its common stock. All of the shares in the offering are being offered by Catalys

In addition, Catalyst expects to grant the underwriters of the offering a 30-day option to purchase up to an additional 15% of the number of shares of common stock offered in the public offering. All

The

“Mr. Musil brings a deep understanding of capital markets, financial strategy and M&A; experience to the Company and we are delighted to have him join Catalyst’s executive leadership team,” said

The poster, entitled: “Phase 2b Trial to evaluate the safety and factor IX levels of a daily subcutaneous prophylaxis treatment regimen of dalcinonacog alfa in Hemophilia B” presented by Howard Le

Connor Clark & Lunn Investment Management Ltd. bought a new stake in Catalyst Biosciences Inc (NASDAQ:CBIO) during the 1st quarter, according to its most recent filing with the Securities and Exchange

Biotech stocks came under pressure along with the broader market in the week ended June 12, as a worsening pandemic situation and its impact on the economy led to an across-the-...